243 related articles for article (PubMed ID: 22407831)
1. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
[TBL] [Abstract][Full Text] [Related]
3. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
[TBL] [Abstract][Full Text] [Related]
6. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.
Liu X; Gao R; Dong Y; Gao L; Zhao Y; Zhao L; Zhao X; Zhang H
BMC Cancer; 2010 Aug; 10():418. PubMed ID: 20698994
[TBL] [Abstract][Full Text] [Related]
7. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
[TBL] [Abstract][Full Text] [Related]
8. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
9. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
10. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.
Karube K; Nabeshima K; Ishiguro M; Harada M; Iwasaki H
J Clin Pathol; 2006 Feb; 59(2):160-5. PubMed ID: 16443732
[TBL] [Abstract][Full Text] [Related]
11. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
[TBL] [Abstract][Full Text] [Related]
12. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase.
Lee MJ; Tsai YJ; Lin MY; You HL; Kalyanam N; Ho CT; Pan MH
Phytomedicine; 2019 Apr; 57():377-384. PubMed ID: 30831486
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Lopez G; Pollock RE
Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
[TBL] [Abstract][Full Text] [Related]
15. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
16. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
19. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).
Alaggio R; Turrini R; Boldrin D; Merlo A; Gambini C; Ferrari A; Dall'igna P; Coffin CM; Martines A; Bonaldi L; De Salvo GL; Zanovello P; Rosato A
PLoS One; 2013; 8(11):e80456. PubMed ID: 24303016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
